06

May2021

PMPRB Announces the Guideline Monitoring and Evaluation Plan (GMEP) Consultation

The PMPRB is developing a Guideline Monitoring and Evaluation Plan (GMEP) that will analyze trends in the pharmaceutical market before and after the implementation of the new framework to assess whether it is working as intended, and to inform the need for any future adjustments. The PMPRB ... Read More

19

Apr2021

Breaking News: 2 Reporting Periods for PMPRB MLP Compliance for Grandfathered and Gap Medicines

The PMPRB has announced it has revisited it’s March 17, 2021 decision regarding timelines for compliance for Grandfathered and Gap medicines.  The Board has reset the maximum list price (MLP) compliance timeline for these drugs to 2 PMPRB reporting periods, rather than their amended 1 reporting period timeline. MLP compliance for ... Read More

29

Mar2021

Patented Medicine Prices Review Board (PMPRB) 2019 Annual Report Published

The PMPRB has published the long awaited 2019 Annual Report. The following are some of the high-level takeaways: Sales of patented medicines in Canada reached $17.2 billion in 2019, a moderate increase of 3.5% from the ... Read More

18

Mar2021

PMPRB February 15th Consultation – Decision made for Gap Medicines and Timelines for Compliance

On January 15, 2021, PMPRB invited stakeholders to comment on two key amendments to the final guidelines that were originally to come into affect for January 1, 2021 but were delayed to July 1, 2021. PMPRB received 48 submissions in response to the definition of Gap Medicines and ... Read More

19

Feb2021

PDCI Launches Sharing Page for Submissions to the PMPRB Proposed Amendments to the New Guidelines

On December 29, 2020, the coming into force date for the amended PMPRB regulations and guidelines were further delayed to July 1, 2021.  The PMPRB has invited stakeholders to comment on two critical amendments to the regulations with responses due by February 15th. Specifically, the PMPRB proposes ... Read More

15

Jan2021

PMPRB Proposes Amendments to New Guidelines: Requests Consultation from Stakeholders

On January 13th 2021, as a consequence of the new PMPRB coming-into-force date, PMPRB has invited stakeholders to comment on two proposed amendments to the New Guidelines.  The two amendments pertain to (A) the Definition of Gap Medicines and (B) Compliance Timelines with Maximum List ... Read More

15

Jan2021

Released: PMPRB11 Potential Sources for Foreign Prices

The PMPRB has released a list of potential sources for prices in the PMPRB 11 basket of reference countries. A non-exhaustive list of examples of potential foreign sources can be found here. Starting July 1, 2021, the Patented Medicines Regulations will require patentees to ... Read More

06

Jan2021

PMPRB Publishes New CPI Factors for 2021 Price Increases

The delay in the implementation of the new Patented Medicines Regulations to July 1, 2021 means that patentees can take 2021 price increases on medicines under PMPRB jurisdiction. PMPRB has released the 2021 CPI-Based Price-Adjustment Factors for Patented Drug ... Read More

29

Dec2020

Patented Medicines Regulations/PMPRB Guidelines Delayed Until July 1, 2021

Health Canada has announced that the implementation of the Patented Medicines Regulations and Final PMPRB Guidelines has been delayed for 6 months to July 1, 2021. Health Canada stated that the primary reason for the delay are the challenges posed by COVID-19 for all stakeholders. Additionally, Health Canada stated ... Read More

08

Dec2020

PMPRB Webinar on Online Filing Tool (December 7, 2020) – Attachment Included

Today the PMPRB hosted a webinar for their new online filing tool which will be available to all patentees as of January 1st, 2021. The webinar revealed a new Form 4 (which will provide PMPRB with the National Market size estimation for new medicines) along with a walk through of the ... Read More